Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Endometrial Neoplasms 20Anorexia 11Cachexia 9Neoplasms 8Breast Neoplasms 8Endometrial Hyperplasia 7Weight Loss 3Recurrence 2Overweight 2Obesity 2Lung Neoplasms 2Head and Neck Neoplasms 2Body Weight Changes 2Body Weight 2Vomiting 1Turcot syndrome 1Squamous Intraepithelial Lesions 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Prosthesis Failure 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Nutrition Disorders 1Neoplasms, Second Primary 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mesothelioma, Malignant 1Menorrhagia 1

Interventions

telapristone acetate 18ulipristal acetate 17Uterine Myomectomy 13vilaprisan 12Leuprolide 11relugolix 9estradiol, norethindrone drug combination 9asoprisnil 9elagolix 7Uterine Artery Embolization 7Mifepristone 7Estradiol 7Bupivacaine 7ulipristal 6Tranexamic Acid 6Saline Solution 5Norethindrone Acetate 5linzagolix 4epigallocatechin gallate 4Sodium Chloride 4Letrozole 4Hysterectomy 4Vitamin B 6 3Sugars 3Misoprostol 3Lidocaine 3Gonadotropin-Releasing Hormone 3Embolization, Therapeutic 3cetrorelix 2Vitamin D 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Leiomyoma × Megestrol Acetate × Clear all
NCT06671548 2026-02-02

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
120 enrolled

Leiomyoma, Menorrhagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡